DDInter1123 DDInter1948
Mannitol is an osmotic diuretic that is metabolically inert in humans and occurs naturally, as a sugar or sugar alcohol, in fruits and vegetables. Mannitol elevates blood plasma osmolality, resulting in enhanced flow of water from tissues, including the brain and cerebrospinal fluid, into interstitial fluid and plasma. As a result, cerebral edema, elevated intracranial pressure, and cerebrospinal fluid volume and pressure may be reduced. Mannitol may also be used for the promotion of diuresis before irreversible renal failure becomes established; the promotion of urinary excretion of toxic substances; as an Antiglaucoma agent; and as a renal function diagnostic aid. On October 30, 2020, mannitol was approved by the FDA as add-on maintenance therapy for the control of pulmonary symptoms associated with cystic fibrosis in adult patients and is currently marketed for this indication under the name BRONCHITOL® by Chies
Vortioxetine is an antidepressant medication indicated for the treatment of major depressive disorder (MDD). It is classified as a serotonin modulator and stimulator (SMS) as it has a multimodal mechanism of action towards the serotonin neurotransmitter system whereby it simultaneously modulates one or more serotonin receptors and inhibits the reuptake of serotonin. More specifically, vortioxetine acts via the following biological mechanisms: as a serotonin reuptake inhibitor (SRI) through inhibition of the serotonin transporter, as a partial agonist of the 5-HT1B receptor, an agonist of 5-HT1A, and an antagonist of the 5-HT3, 5-HT1D, and 5-HT7 receptors. SMSs were developed because there are many different subtypes of serotonin receptors, however, not all of these receptors appear to be involved in the antidepressant effects of SRIs. Some serotonin receptors seem to play a relatively neutral or insignificant role in the regulation of mood, but others, such as 5-HT1A autoreceptors and 5-HT7 receptors, appear to play an oppositional role in the efficacy of SRIs in treating depression.
Mannitol {u} (Compound) causes {v} (Side Effect) Hypersensitivity
Hypersensitivity {u} (Side Effect) is caused by {v} (Compound) Prasugrel
Prasugrel {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Vortioxetine
Mannitol {u} (Compound) causes {v} (Side Effect) Urinary tract disorder
Urinary tract disorder {u} (Side Effect) is caused by {v} (Compound) Doxepin
Doxepin {u} may lead to a major life threatening interaction when taken with {v} Vortioxetine
Mannitol {u} (Compound) binds {v} (Gene) ABCB1
ABCB1 {u} (Gene) is bound by {v} (Compound) Dipyridamole
Dipyridamole {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Vortioxetine
Mannitol {u} (Compound) binds {v} (Gene) ABCB1
ABCB1 {u} (Gene) is bound by {v} (Compound) Doxepin
Doxepin {u} may lead to a major life threatening interaction when taken with {v} Vortioxetine
Mannitol (Compound) causes Hypersensitivity (Side Effect) and Hypersensitivity (Side Effect) is caused by Prasugrel (Compound) and Prasugrel may cause a moderate interaction that could exacerbate diseases when taken with Vortioxetine
Mannitol (Compound) causes Urinary tract disorder (Side Effect) and Urinary tract disorder (Side Effect) is caused by Doxepin (Compound) and Doxepin may lead to a major life threatening interaction when taken with Vortioxetine
Mannitol (Compound) binds ABCB1 (Gene) and ABCB1 (Gene) is bound by Dipyridamole (Compound) and Dipyridamole may cause a moderate interaction that could exacerbate diseases when taken with Vortioxetine
Mannitol (Compound) binds ABCB1 (Gene) and ABCB1 (Gene) is bound by Doxepin (Compound) and Doxepin may lead to a major life threatening interaction when taken with Vortioxetine